PepGen announced the appointment of Howard Mayer, M.D. to the PepGen Board of Directors, effective November 15, 2023. Dr. Mayer was most recently Executive Vice President, Head of Research and Development at Ipsen Pharmaceuticals from 2019 until 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PEPG:
- PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
- PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
- PepGen reports Q3 EPS (98c), consensus (88c)
- PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
- PepGen announces FDA lifted clinical hold on its IND for FREEDOM-DM1
